Table 1.

Side effects by cohort. The table reports the number of individuals meeting criteria for adverse events and includes only those symptoms reported by two or more participants in any cohort. Sinusitis and UPDRS reported as mean change in absolute score from baseline, by cohort.

Table of Side Effects
	Placebo	300 mg/d	600 mg/d
	(n=9)	(n=8)	(n=8)
Number of individuals reporting symptom:
Negative Side Effects
Labored breathing	0	0	2
Sore throat/redness	0	0	2
Flatulence	2	0	1
Increased thirst	0	0	2
Contortions/neck-back arching	0	2	0
Chills	2	0	0
Positive Side Effects
Improved blink rate	1	5	0
Improved arm swing	1	1	2
Fewer muscle pains or aches	2	1	2
Reduced edema	0	0	2
Improved incontinence/Nocturnal enuresis	0	2	0
Reduced urinary frequency	3	0	0
Reduced agitation	0	3	0
Improved drowsiness/lethargy/sedation	2	1	2
Improved insomnia	1	0	2
Less crying/feelings of sadness	2	0	0
Deviation from laboratory normal reference ranges
Hemoglobin	0	0	2
Hematocrit	0	0	2
Creatine	1	1	2
Uric acid	0	0	2
Change from baseline, Mean (SD):
Sinusitis (SNOT-20 Score 0–1)	0.275	0.185	0.213
Change in Parkinson's Symptoms
UPDRS total (0–199)	−1.1 (4.1)	−5.3 (4.8)	−4.3 (7.5)
UPDRS Part 1: Mentation, behavior, & mood	−0.6(1.2)	−1.4(2.0)	−0.8(1.7)
UPDRS Part 2: Activities of daily living	−1.3(3.5)	−0.8 (2.3)	−1.3(3.5)
UPDRS Part 3: Motor score	0.8 (3.7)	−3.1 (2.9)	−1.4(3.7)
UPRDS Part 4: Complications of dopaminergic therapy	1.0(1.5)	−0.1 (1.0)	−0.9 (2.4)